title: Adjuvant TKIs in NSCLC: what can we learn from RADIANT?
authors.affiliation: Division of Medical Oncology, University of Colorado, 12801 East 17th Avenue, Aurora, CO 80045, USA.
authors.forename: Fred R
authors.initials: FR
authors.lastname: Hirsch
authors.affiliation: Division of Medical Oncology, University of Colorado, 12801 East 17th Avenue, Aurora, CO 80045, USA.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Bunn
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male
chemical_list: D000970:Antineoplastic Agents; D000069347:Erlotinib Hydrochloride